|
3.1 Tabac
|
|
|
|
5. Traitements
|
|
|
|
5.2 Pharma
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
New treatment for patients with multiple myeloma [EMA]
|
|
|
|
|
|
The
CHMP’s recommendation is based on two studies. In one study of 106
patients receiving Darzalex, tumours shrank or could no longer be seen
in 29% of the patients over an average of 7.4 months. In the second
study of 42 patients receiving Darzalex, tumours shrank or could no
longer be seen in 36% of patients.
|
|
|
|
|
|
|
|
Halaven [EMA]
|
|
|
|
|
|
The
CHMP adopted a new indication as follows: "treatment of adult patients
with unresectable liposarcoma who have received prior anthracycline
containing therapy (unless unsuitable) for advanced or metastatic
disease".
|
|
|
|
|
|
|
Opdivo [EMA]
|
|
|
|
|
|
“Opdivo
as monotherapy or in combination with ipilimumab is indicated for the
treatment of advanced (unresectable or metastatic) melanoma in adults.
Relative to nivolumab monotherapy, an increase in progression-free
survival (PFS) for the combination of nivolumab with ipilimumab is
established only in patients with low tumour PD-L1 expression (see
section 4.4 and 5.1).”
|
|
|
|
|
|
|
Darzalex [EMA]
|
|
|
|
|
|
Darzalex should be administered by a healthcare professional, in an environment where resuscitation facilities are available.
|
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
6.8 Communication
|
|
|